Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuronASX:IMC +2.63% Cash-to-Debt is 56.72 as of Jun. 2026, which is 45% below its 10-year median of 103.14. The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, Immuron ranks better than 71.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immuron's cash to debt ratio for the quarter that ended in Jun. 2026 was 56.72.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Immuroncould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Immuron's Cash-to-Debt or its related term are showing as below:
ASX:IMC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 10.92 Med: 103.14 Max: No Debt
Current: 56.72
During the past 13 years, Immuron's highest Cash to Debt Ratio was No Debt. The lowest was 10.92. And the median was 103.14.
ASX:IMC's Cash-to-Debt is ranked better than 71.86% of 1393
companies
in the Biotechnology industry
Industry Median: 6.78
vs ASX:IMC: 56.72
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Immuron Cash-to-Debt Related Terms
Immuron Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Immuron's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:IMC vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Immuron's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Immuron's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a Cash-to-Debt of 56.72 as of Jun. 2026. This is 45% below median its historical median of 103.14. Over the past decade, Immuron's Cash-to-Debt has ranged from 10.92 to 10,000.00. According to the industry distribution chart, Immuron ranks #392 out of 1393 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Immuron's Cash-to-Debt too high?
Immuron's current Cash-to-Debt of 56.72 is 45% below median its 10-year median of 103.14. Over the past 10 years, this metric has ranged from a low of 10.92 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Immuron's value of 56.72 is 736.6% above this industry median. Based on the distribution chart, Immuron ranks #392 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint.
How does Immuron's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #392 out of 1393 companies for Cash-to-Debt. This puts Immuron in the upper half of its industry. The industry median Cash-to-Debt is 6.78. Immuron's value of 56.72 is 736.6% above this benchmark. Historically, Immuron's own Cash-to-Debt has ranged from 10.92 to 10,000.00 over the past decade. While the company's 10-year median is 103.14 vs. the industry median of 6.78, Immuron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuron's current Cash-to-Debt of 56.72 is 736.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Cash-to-Debt is 56.72, which is 45% below median its own 10-year median of 103.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (ASX:IMC) has a current Cash-to-Debt of 56.72. The current Cash-to-Debt is 56.72, which is 45% below median its 10-year median of 103.14 and 736.6% above the Biotechnology industry median of 6.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Cash-to-Debt is 56.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 
